CLDX Celldex Therapeutics Inc
Price (delayed)
$17.38
Market cap
$1.15B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.45
Enterprise value
$1.13B
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which
Highlights
CLDX's EPS is up by 16% YoY and by 5% from the previous quarter
Celldex Therapeutics's equity has soared by 74% YoY but it has decreased by 4.9% from the previous quarter
CLDX's quick ratio is up by 34% year-on-year but it is down by 22% since the previous quarter
The debt has soared by 50% YoY and by 24% QoQ
The company's gross profit fell by 30% QoQ
Key stats
What are the main financial stats of CLDX
Market
Valuations
Earnings
Shares outstanding
66.38M
Market cap
$1.15B
Enterprise value
$1.13B
Price to earnings (P/E)
N/A
Price to book (P/B)
1.54
Price to sales (P/S)
159.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
160.86
Revenue
$7.02M
Gross profit
$7.02M
Operating income
-$195.08M
Net income
-$157.86M
EBIT
-$157.86M
EBITDA
-$154.69M
Free cash flow
-$159.7M
Per share
Balance sheet
Liquidity
EPS
-$2.45
EPS diluted
-$2.45
Free cash flow per share
-$2.48
Book value per share
$11.26
Revenue per share
$0.11
TBVPS
$11.88
Total assets
$792.34M
Total liabilities
$45.34M
Debt
$3.81M
Equity
$747.01M
Working capital
$707.66M
Debt to equity
0.01
Current ratio
18.91
Quick ratio
18.38
Net debt/EBITDA
0.16
Margins
Efficiency
Dividend
EBITDA margin
-2,203.5%
Gross margin
100%
Net margin
-2,248.8%
Operating margin
-2,778.9%
Return on assets
-19%
Return on equity
-19.8%
Return on invested capital
-21.9%
Return on capital employed
-21%
Return on sales
-2,248.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CLDX stock price
How has the Celldex Therapeutics stock price performed over time
Intraday
3.15%
1 week
-11.19%
1 month
-15.51%
1 year
-57.77%
YTD
-31.22%
QTD
-4.24%
Financial performance
How have Celldex Therapeutics's revenue and profit performed over time
Revenue
$7.02M
Gross profit
$7.02M
Operating income
-$195.08M
Net income
-$157.86M
Gross margin
100%
Net margin
-2,248.8%
CLDX's operating margin is down by 49% since the previous quarter and by 24% year-on-year
The net margin has decreased by 46% QoQ and by 9% YoY
The company's gross profit fell by 30% QoQ
Celldex Therapeutics's revenue has decreased by 30% from the previous quarter
Growth
What is Celldex Therapeutics's growth rate over time
Valuation
What is Celldex Therapeutics stock price valuation
P/E
N/A
P/B
1.54
P/S
159.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
160.86
CLDX's EPS is up by 16% YoY and by 5% from the previous quarter
Celldex Therapeutics's equity has soared by 74% YoY but it has decreased by 4.9% from the previous quarter
The P/B is 63% lower than the 5-year quarterly average of 4.1 and 44% lower than the last 4 quarters average of 2.7
CLDX's price to sales (P/S) is 63% lower than its 5-year quarterly average of 422.2 and 47% lower than its last 4 quarters average of 289.7
Celldex Therapeutics's revenue has decreased by 30% from the previous quarter
Efficiency
How efficient is Celldex Therapeutics business performance
Celldex Therapeutics's ROIC has soared by 60% YoY and by 9% from the previous quarter
The ROE has soared by 56% YoY and by 8% from the previous quarter
The ROA has soared by 54% YoY and by 7% QoQ
CLDX's ROS is down by 46% from the previous quarter and by 9% YoY
Dividends
What is CLDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CLDX.
Financial health
How did Celldex Therapeutics financials performed over time
Celldex Therapeutics's total assets has soared by 70% YoY but it has decreased by 3.7% from the previous quarter
The current ratio has increased by 36% YoY but it has decreased by 22% from the previous quarter
The debt is 99% lower than the equity
Celldex Therapeutics's equity has soared by 74% YoY but it has decreased by 4.9% from the previous quarter
The debt has soared by 50% YoY and by 24% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.